Oral Isotretinoin — Resident Study Notes
Pharmacology
13-cis-retinoic acid; oral bioavailability ~ 25% (must take with fat for adequate absorption — 2× higher with food). Lipophilic; isomerizes to all-trans-RA (active form). Half-life 10-20 h. Dose-dependent reduction in sebum (50-90%), comedolysis, antimicrobial (reduced C. acnes via altered sebum), anti-inflammatory (downregulates TLR2, neutrophil chemotaxis).
Indications
- FDA-approved: severe nodulocystic acne, recalcitrant moderate-severe acne
- Off-label (with evidence): rosacea (low-dose, granulomatous, refractory), hidradenitis suppurativa (less effective for HS itself), folliculitis decalvans, dissecting cellulitis, Gram-negative folliculitis, cutaneous neoplasia chemoprevention (xeroderma pigmentosum, organ transplant)
Dosing Science
- Standard: 0.5-1.0 mg/kg/day; cumulative target 120-150 mg/kg (lower relapse vs 60-100)
- Newer evidence: 180-220 mg/kg cumulative for high-relapse-risk (very young, severe disease, persistent flare)
- Low-dose protocol: 0.25-0.4 mg/kg/day for adult acne, rosacea — fewer side effects, longer course
- Pulse / intermittent: 1 week/month — limited evidence
- Total duration: typically 5-9 months
Pre-Treatment Screening
- Pregnancy test (women, β-hCG); 2 contraceptives required throughout + 1 month post
- CBC, AST/ALT, fasting lipid panel
- Optional: CK if athletic patient, bone density if < 18 yo with risk factors
Adverse Events
| System | Common AEs | Management |
|---|---|---|
| Mucocutaneous | Cheilitis, xerosis, eczema, photosensitivity, retinoid dermatitis, paronychia | Lip balm, ceramide moisturizer, sunscreen; topical / intralesional steroid for severe |
| Ocular | Dry eye, blepharitis, decreased night vision | Artificial tears; warn re: night driving; ophthalmology if severe |
| Musculoskeletal | Myalgia, arthralgia, CK elevation, hyperostosis (long-term high-dose) | Reduce dose if symptomatic; warn athletes |
| Hepatic | AST/ALT elevation (10-15%) | Hold if > 3× ULN; rarely permanent |
| Lipid | Elevated TG / cholesterol | Diet, fibrate / fish oil if TG > 500 |
| GI | IBD association — controversial; nausea, dyspepsia | 2024 evidence weakens IBD causal link; observe |
| Neuropsych | Depression risk — controversial; pseudotumor cerebri (IIH) with concurrent tetracyclines | Screen depression; do NOT combine with doxycycline / minocycline |
| Teratogenicity | Category X — severe craniofacial, cardiac, CNS malformations | 2 contraception methods, monthly pregnancy tests, 1 month post-treatment |
Drug Interactions
- Tetracyclines (doxycycline, minocycline): avoid concurrent — pseudotumor cerebri risk
- Vitamin A supplements: avoid (additive hypervitaminosis A)
- Methotrexate: increased hepatotoxicity
- Phenytoin: increased osteomalacia risk
- Hormonal contraceptives: isotretinoin doesn't reduce efficacy (St John's wort, however, does)
Post-Isotretinoin Procedures
- Traditional: avoid ablative resurfacing × 6 months post (atypical scarring concern)
- Updated ASDS 2017 / AAD 2024: case-by-case; many procedures (laser hair removal, non-ablative fractional, microneedling) safe within 1-3 months post; ablative laser, dermabrasion still defer 6 months
Key Controversies
- Depression / suicidality: meta-analyses inconsistent; FDA black-box maintains. Screen at baseline + each visit; document
- IBD: large 2024 meta-analyses show no causal link; previous case-controls confounded by pre-IBD acne
- Hyperostosis / DISH: with long-term high-dose; uncommon at standard acne doses
AAD 2024 Acne Guideline Integration
Strong recommendation for: severe acne, scarring acne, psychosocial-burden acne, or failure of standard topical / oral antibiotic. Combined oral antibiotics + retinoid is preferred initial therapy for moderate cases; isotretinoin reserved when these fail.
NICE NG198 Integration (2021, updated April 2026)
- Daily dose 0.5–1 mg/kg; reduced < 0.5 mg/kg if increased AE risk
- Cumulative target 120–150 mg/kg; may stop sooner if clear ≥ 4–8 weeks (1.5.25)
- Mandatory baseline mental-health screen + reassessment at every visit (post-2023 MHRA amendment, reconfirmed April 2026); also counsel re: sexual function
- Refer to mental-health services pre-treatment if active concerns
- UK Pregnancy Prevention Programme (MHRA acknowledgement-of-risk form; monthly β-hCG)
- UK supply chain: only consultant-led teams or accredited GPwERs may initiate (since October 2023)
- Add prednisolone if acne flare on initiation; add prednisolone routinely when starting iso for acne fulminans (1.5.27-28)
References
- Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-e30. doi:10.1016/j.jaad.2023.12.017 [Source]
- National Institute for Health and Care Excellence. Acne vulgaris: management (NG198). London: NICE; 2021 (last updated April 2026). [Source]
- Layton AM. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162-169.
- Wright S, et al. Isotretinoin and IBD: propensity-matched cohort. JAAD. 2021;84(4):963-971.
- Spring LK, et al. ASDS consensus on isotretinoin and procedural timing. JAMA Dermatol. 2017;153(8):802-809.
Patient handout: see Isotretinoin Patient Education for plain-language version.